LPCN 1021 clinical trials
Also written LPCN 1021.
How each study uses LPCN 1021 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- LPCN 1021
- 3
Studies by the year they started
4 studies that test it; most in 2014 (1)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 3
- 4
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Lipocine Inc. (4)
Studies
Open first, then newest update. How each study uses LPCN 1021 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- Ambulatory Blood Pressure Monitoring in Oral Testosterone Undecanoate (TU, LPCN 1021) Treated Hypogonadal MenCompletedPhase 3Lipocine Inc.NCT03868059Written as LPCN 1021
- Dosing Flexibility Study of Oral Testosterone Undecanoate (TU, LPCN 1021)CompletedPhase 3Lipocine Inc.NCT03242408Written as LPCN 1021
- Dosing Validation Study of Oral Testosterone Undecanoate (TU, LPCN 1021).CompletedPhase 3Lipocine Inc.NCT03242590Written as LPCN 1021
- Safety and Efficacy of Oral LPCN 1021 in Men With Low Testosterone or HypogonadismCompletedPhase 3Lipocine Inc.NCT02081300Written as Oral testosterone undecanoate, LPCN 1021